We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UROY:NASDAQUranium Royalty Corp. Analysis

Data as of 2026-09-01 - not real-time

$4.21

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Uranium Royalty Corp. is priced at $4.21, and its moving averages give no clean directional read — the structure is neutral. It has gained 52.5% over the past 30 days. With RSI at 61.2 the momentum picture is approaching overbought, alongside a bearish MACD signal. Price has been bracketed by support at $3.34 and resistance at $4.48.
Multiples put this in undervalued territory: 14.5 times earnings against the sector's 21.6. Revenue is growing at 4342.6% on a 21.5% profit margin.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 69.4%, a beta of 2.38 and a maximum drawdown of 52.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 6/10 long-term conviction.

Top Market Events

LAKEWOOD, Colo., Aug. 7, 2026 /CNW/ -- Uranium Royalty Corp. NASDAQ: UROY   " URC " or the " Company " today announced...Uranium Royalty Corp. NASDAQ: UROY TSX: URC "URC" or the "Company" is pleased to announce that it has completed its...Uranium Royalty Corp. NASDAQ: UROY "URC" or the "Company" today announced the appointment of Kevin McQuilkin and Peter...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 3.70
  • MACD momentum is negative
  • 30-day price change of +52.5%

Medium Term

1–3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 14.5 versus sector average of 21.6
  • Trading above the 200-day average of 3.70
  • 30-day volatility of 69.4%

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 14.5 versus sector average of 21.6
  • Profit margin of 21.5% is healthy
  • Revenue growth of +4342.6%

Key Metrics & Analysis

Financial Health

Revenue Growth4342.60%
Profit Margin21.53%
P/E Ratio14.5
ROE15.25%
ROA10.74%
Debt/Equity0.04
P/B Ratio2.0
Op. Cash Flow$178.5M
Free Cash Flow$169.6M
Industry P/E21.6

Technical Analysis

TrendNeutral
RSI61.2
Support$3.34
Resistance$4.48
MA 20$4.12
MA 50$3.37
MA 200$3.70
MACDBearish
VolumeDecreasing
Fear & Greed Index93.21

Valuation

Fair Value$16.11
Target Price$4.11
Upside/Downside-2.45%
GradeUndervalued
TypeBlend

Risk Assessment

Beta2.38
Volatility69.39%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.